Cullinan Oncology
CGEM
137 hedge funds and large institutions have $1.09B invested in Cullinan Oncology in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 67 increasing their positions, 28 reducing their positions, and 17 closing their positions.
431% more call options, than puts
Call options by funds: $11.1M | Put options by funds: $2.1M
139% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 28
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
2.93% more ownership
Funds ownership: 109.18% → 112.11% (+2.9%)
1% more funds holding
Funds holding: 135 → 137 (+2)
1% less capital invested
Capital invested by funds: $1.1B → $1.09B (-$10.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$17.7M |
| 2 |
PSC
Patient Square Capital
Menlo Park,
California
|
+$14.6M |
| 3 |
Millennium Management
New York
|
+$14M |
| 4 |
BlackRock
New York
|
+$14M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$20.1M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$19.6M |
| 3 |
AG
Artal Group
Luxembourg
|
-$18.5M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.6M |
| 5 |
PA
Perceptive Advisors
New York
|
-$13.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Pacer Advisors
Malvern,
Pennsylvania
| – | -$10.4K | -595 | Closed |
|
152
Osaic Holdings
Scottsdale,
Arizona
| – | -$872 | -50 | Closed |
|
153
Group One Trading
Chicago,
Illinois
| – | -$248 | -14 | Closed |
|
|
C
154
Covestor
London,
United Kingdom
| – | -$18 | -1 | -20% |
|
CGEM Hedge Fund Activity: Q3 2024 in Review
137 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q3 2024, worth a combined $1.09B — down 0.94% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CGEM positions and 17 closed out — a net gain of 2 holders — while 67 added to existing stakes and 28 trimmed.
The largest buyer was Braidwell, adding an estimated $17.7M. The largest seller was Avidity Partners Management, cutting an estimated $20.1M.
- 137 institutional investors held Cullinan Oncology (CGEM) as of Q3 2024, up from 135 in Q2 2024.
- Funds reported $1.09B of Cullinan Oncology stock for Q3 2024, down 0.94% quarter-over-quarter.
- 19 funds opened new Cullinan Oncology positions in Q3 2024 and 17 closed out, a net change of +2 holders.
- The largest Cullinan Oncology buyer in Q3 2024 was Braidwell, an estimated $17.7M added.
- The largest Cullinan Oncology seller in Q3 2024 was Avidity Partners Management, an estimated $20.1M sold.
Based on aggregated 13F filings for Q3 2024.